Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Shanghai 6th People's Hospital is the lead sponsor of 32 current clinical trials in our China register. 30 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Anlotinib, Bevacizumab and Calcium folinate. The most-studied condition is Traumatic Brain Injury.

ClinicalTrials.gov trials by status

Recruiting3094%
Not yet open26%

Trials by phase

Observational2063%
Not applicable619%
Phase 1/226%
Phase 226%
Phase 413%
Phase EARLY_PHASE113%

Clinical trials sponsored by Shanghai 6th People's Hospital

32 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Validation of Five Seasons Sleep Tracking Mat for the Diagnosis of Obstructive Sleep Apnea NCT06875479 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea (OSA)	Observational	Recruiting	2025-04	China
Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care NCT06241482 · ClinicalTrials.gov ↗ · Neurocritical Care, Traumatic Brain Injury, Cerebrovascular Disease	Not applicable	Recruiting	2024-10	China
Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control NCT06591286 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2	Not applicable	Recruiting	2024-10	China
Development and Validation of a Digital Twin-based Clinical Research System (X Town Stage I) NCT06861283 · ClinicalTrials.gov ↗ · Chronic Disease	Observational	Recruiting	2025-04	China
MRI Performance and Risk Factors in Bilateral Vestibular Hypofunction NCT07709143 · ClinicalTrials.gov ↗ · Bilateral Vestibular Hypofunction, Bilateral Vestibulopathy, Presbyvestibulopathy	Observational	Recruiting	2024-10	China
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC NCT07482891 · ClinicalTrials.gov ↗ · Chemotherapy-induced Nausea and Vomiting Drugs: Dexamethasone, Fosrolapitant and Palonosetron Hydrochloride, Olanzapine	Phase 4	Recruiting	2026-03	China
Safety and Preliminary Efficacy of iEVs Injection in Treating Lateral Epicondylitis of Humerus NCT07111325 · ClinicalTrials.gov ↗ · Lateral Epicondylitis	Phase 1/2	Recruiting	2023-07	China
Nomogram for Predicting Difficult Laparoscopic Appendectomy NCT06818942 · ClinicalTrials.gov ↗ · Emergencies	Observational	Recruiting	2025-01	China
CGM for Insulin-Treated T2DM During Post-Discharge Transition NCT07414277 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM)	Not applicable	Recruiting	2026-05	China
Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS) NCT06730321 · ClinicalTrials.gov ↗ · Thyroid Cancer, Thyroid Nodule, Thyroid Diseases	Observational	Recruiting	2024-12	China
Public Perceptions Toward Robotic Surgery, Telesurgery and Telemedicine NCT06803719 · ClinicalTrials.gov ↗ · Robotic Surgery, Telemedicine	Observational	Recruiting	2024-11	China
Effect of Continuous Glucose Monitoring System on Glycemic Control in Non-insulin-Treated Elderly People With Type 2 Diabetes NCT07007676 · ClinicalTrials.gov ↗ · Diabetes Mellitus Type 2	Not applicable	Recruiting	2025-07	China
A Prospective Cohort Study of Surgical Treatment for Foot Deformities in HSP NCT06936163 · ClinicalTrials.gov ↗ · Hereditary Spastic Paraplegia	Observational	Recruiting	2025-03	China
A Prospective Cohort Study of ITB Treatment for HSP NCT06844734 · ClinicalTrials.gov ↗ · Hereditary Spastic Paraplegia	Observational	Recruiting	2025-01	China
Clinical and Molecular Biological Data Collection and Analysis in Patients With TBI NCT05533060 · ClinicalTrials.gov ↗ · Traumatic Brain Injury	Observational	Recruiting	2022-09	China
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM NCT06590259 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastasis Drugs: Bevacizumab, Cetuximab, Folfiri	Phase 2	Recruiting	2024-03	China
Salivary Cortisol and Hypercortisolism in Type 2 Diabetes NCT07156370 · ClinicalTrials.gov ↗ · Hypercortisolism, Type 2 Diabetes (T2DM)	Observational	Recruiting	2025-09	China
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma NCT07359053 · ClinicalTrials.gov ↗ · Sarcoma Drugs: Anlotinib, Gemcitabine, Lenvatinib	Phase 2	Recruiting	2025-12	China
Postoperative Pain of Robotic, Endoscopic and Open Lateral Neck Dissection NCT06803732 · ClinicalTrials.gov ↗ · Pain, Postoperative, Thyroid Diseases, Surgery	Observational	Recruiting	2024-11	China
A Deep Learning Model for Blood Volume Estimation From Multi-modal Ultrasound NCT06957587 · ClinicalTrials.gov ↗ · Blood Volume Analysis, Ultrasound, Machine Learning	Observational	Recruiting	2025-10	China
Correlation Between Intestinal Microecology Imbalance and Stroke in Young Adults NCT05113043 · ClinicalTrials.gov ↗ · Ischemic Stroke, Hemorrhagic Stroke	Observational	Recruiting	2022-02	China
Renovated Prediction Model for Difficult Transoral and Submental Endoscopic Thyroidectomy NCT06738888 · ClinicalTrials.gov ↗ · Thyroid Cancer, Thyroid Diseases, Thyroid Nodule	Observational	Recruiting	2024-05	China
Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy NCT06671184 · ClinicalTrials.gov ↗ · Differentiated Thyroid Cancer	Observational	Recruiting	2021-01	China
Neural Mechanism of Cerebrocardiac Syndrome Following Traumatic Brain Injury NCT06958406 · ClinicalTrials.gov ↗ · Traumatic Brain Injury, Cerebrocardiac Syndrome	Observational	Recruiting	2025-08	China
Establishment and Clinical Application of Reference Intervals of Salivary Cortisol NCT07168122 · ClinicalTrials.gov ↗ · Healthy Adult, Cushing Syndrome, Adrenal Insufficiency	Observational	Recruiting	2025-09	China
Effectiveness of WeChat-Supported Neck Rehabilitation Exercises on Early Recovery After Thyroidectomy NCT07707401 · ClinicalTrials.gov ↗ · Thyroid Diseases, Thyroid Cancer, Surgery	Not applicable	Recruiting	2026-09	China
The Utility of Thromboelastography in Traumatic Brain Injury NCT04524637 · ClinicalTrials.gov ↗ · Traumatic Brain Injury, Coagulation Disorder	Observational	Recruiting	2018-09	China
Calcium Folinate Treatment of Spastic Paraplegia 56 NCT06478238 · ClinicalTrials.gov ↗ · Hereditary Spastic Paraplegia Drug: Calcium folinate	Phase EARLY_PHASE1	Recruiting	2024-07	China
MRSI Evaluation for Minor Stroke With Large Vessel Occlusion NCT06457217 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke	Observational	Recruiting	2024-08	China
Glucose Pattern in Infertile Women Receiving Assisted Reproduction Using Continuous Glucose Monitoring NCT06863337 · ClinicalTrials.gov ↗ · Infertility Female	Not applicable	Recruiting	2025-03	China
Clinical Evaluation of Salivary 1,5-Anhydroglucitol in Diabetes NCT07781683 · ClinicalTrials.gov ↗ · Type 2 Diabetes (T2DM)	Observational	Not yet open	2026-09	China
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma NCT07632235 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc) Drugs: Celecoxib, Gemcitabine/Cisplatin, Pembrolizumab	Phase 1/2	Not yet open	2026-09	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Shanghai 6th People's Hospital trials

16 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Anlotinib1 Bevacizumab1 Calcium folinate1 Celecoxib1 Cetuximab1 Dexamethasone1 Folfiri1 Fosrolapitant and Palonosetron Hydrochloride1 Gemcitabine1 Gemcitabine/Cisplatin1 Lenvatinib1 MFOLFOX61 Olanzapine1 Paclitaxel Polymer Micelles1 Pembrolizumab1 Sintilimab1

Conditions in Shanghai 6th People's Hospital trials

43 conditions

Traumatic Brain Injury4Thyroid Diseases4Thyroid Cancer3Hereditary Spastic Paraplegia3Thyroid Nodule2Type 2 Diabetes (T2DM)2Surgery2Obstructive Sleep Apnea (OSA)1Neurocritical Care1Cerebrovascular Disease1Moderate or Severe Coma1Diabetes Mellitus, Type 21Chronic Disease1Bilateral Vestibular Hypofunction1Bilateral Vestibulopathy1Presbyvestibulopathy1Chemotherapy-induced Nausea and Vomiting1Lateral Epicondylitis1Emergencies1Type 2 Diabetes Mellitus (T2DM)1Thyroid Cancer, Papillary1Robotic Surgery1Telemedicine1Diabetes Mellitus Type 21

By trial register

Register	Trials	Recruiting
Clinical trials in China	32	30

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Traumatic Brain Injury

Sponsor	Trials
Australian and New Zealand Intensive Care Research Centre	1

Sponsors with the most current trials registered for this condition.

Questions about Shanghai 6th People's Hospital trials

How many clinical trials does Shanghai 6th People's Hospital sponsor?

Shanghai 6th People's Hospital is the lead sponsor of 32 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai 6th People's Hospital trials recruiting?

Yes. 30 of its 32 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai 6th People's Hospital testing?

Its current trials name 16 drugs and biologicals as interventions. The most frequent are Anlotinib (1), Bevacizumab (1), Calcium folinate (1), Celecoxib (1) and Cetuximab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Shanghai 6th People's Hospital clinical trials